Patritumab Deruxtecan

德帕瑞妥单抗

Report date: 2026/05/20 20:02:01
First In Class

Base Information

Drug NamePatritumab Deruxtecan
Drug Alias NameHER3-DXdPatritumab-DX-8951 conjugateU3-1402U3-1402aMK-1022
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > Tetrapeptide linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Camptothecin derivative payload > MAAA-1181a payload
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsDNA topoisomerase I inhibitors
TargetsReceptor tyrosine-protein kinase erbB-3DNA topoisomerase I
Therapy Area/IndicationsBrain metastasesMetastatic breast cancerGastroesophageal Junction Neoplasms +[20] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDaiichi Sankyo (China) Holdings Co LtdLonza Bend IncSamsung Medical Center +[9] 
Inactive CompaniesMerck Sharp & Dohme Corp
Active IndicationsMetastatic breast cancerGastroesophageal Junction NeoplasmsSolid tumours +[18] 
Inactive IndicationsBrain metastasesColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG